Phase I, Open-Label, Multi-Center Study to Evaluate Safety, Pharmacoki
Research payments
$308,196
Through program year 2022, $308,196 in research payments was reported against Phase I, Open-Label, Multi-Center Study to Evaluate Safety, Pharmacoki, across 64 payments, paid by GlaxoSmithKline, LLC..
- Paid by
- GlaxoSmithKline, LLC.
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
2 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2022 | Research | $209,708 | 43 |
| 2021 | Research | $98,488 | 21 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
8 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Monique Barbour Jupiter, FL Named on 10 payments
- Joel Pearlman Modesto, CA Named on 9 payments
- Pamela Weber Commack, NY Named on 5 payments
- Charles Wykoff Bellaire, TX Named on 4 payments
- Victor Gonzalez Harlingen, TX Named on 3 payments
- Christopher Devine Cincinnati, OH Named on 2 payments
- Allan Hunter Springfield, OR Named on 2 payments
- Alexander Brucker Radnor, PA Named on 2 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.